Endo outperform by RBC

RBC Capital Markets analyst Ken Trbovich rated Endo Pharmaceuticals Holdings, Inc. at outperform, above average risk. The analyst made some minor changes to RBC's model based on current prescription trends, raising the 2006 revenue estimate to $902 million from $892 million. Also, the analyst believes Lidoderm may lose some traction in the fourth-quarter 2006 due to Opana being the top priority for Endo's sales force. Shares of the Chadds Ford, Pa.-based pharmaceutical company were down 9 cents, or 0.31%, at $29.39. (Nasdaq: ENDP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.